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Summary
Background Large, rare chromosomal deletions and duplications known as copy number variants (CNVs) have been 
implicated in neurodevelopmental disorders similar to attention-deﬁ cit hyperactivity disorder (ADHD). We aimed to 
establish whether burden of CNVs was increased in ADHD, and to investigate whether identiﬁ ed CNVs were enriched 
for loci previously identiﬁ ed in autism and schizophrenia.
Methods We undertook a genome-wide analysis of CNVs in 410 children with ADHD and 1156 unrelated ethnically 
matched controls from the 1958 British Birth Cohort. Children of white UK origin, aged 5–17 years, who met diagnostic 
criteria for ADHD or hyperkinetic disorder, but not schizophrenia and autism, were recruited from community child 
psychiatry and paediatric outpatient clinics. Single nucleotide polymorphisms (SNPs) were genotyped in the ADHD 
and control groups with two arrays; CNV analysis was limited to SNPs common to both arrays and included only 
samples with high-quality data. CNVs in the ADHD group were validated with comparative genomic hybridisation. We 
assessed the genome-wide burden of large (>500 kb), rare (<1% population frequency) CNVs according to the average 
number of CNVs per sample, with signiﬁ cance assessed via permutation. Locus-speciﬁ c tests of association were 
undertaken for test regions deﬁ ned for all identiﬁ ed CNVs and for 20 loci implicated in autism or schizophrenia. 
Findings were replicated in 825 Icelandic patients with ADHD and 35 243 Icelandic controls.
Findings Data for full analyses were available for 366 children with ADHD and 1047 controls. 57 large, rare CNVs were 
identiﬁ ed in children with ADHD and 78 in controls, showing a signiﬁ cantly increased rate of CNVs in ADHD (0·156 vs 
0·075; p=8·9×10–⁵). This increased rate of CNVs was particularly high in those with intellectual disability (0·424; 
p=2·0×10–⁶), although there was also a signiﬁ cant excess in cases with no such disability (0·125, p=0·0077). An excess 
of chromosome 16p13.11 duplications was noted in the ADHD group (p=0·0008 after correction for multiple testing), 
a ﬁ nding that was replicated in the Icelandic sample (p=0·031). CNVs identiﬁ ed in our ADHD cohort were signiﬁ cantly 
enriched for loci previously reported in both autism (p=0·0095) and schizophrenia (p=0·010).
Interpretation Our ﬁ ndings provide genetic evidence of an increased rate of large CNVs in individuals with ADHD 
and suggest that ADHD is not purely a social construct. 
Funding Action Research; Baily Thomas Charitable Trust; Wellcome Trust; UK Medical Research Council; European 
Union.
Introduction
Attention-deﬁ cit hyperactivity disorder (ADHD), a 
childhood-onset disorder, is characterised by severe and 
impairing inattention, motor hyperactivity, and 
impulsiveness.1,2 It aﬀ ects around 2% of children and 
most of those aﬀ ected continue to show impairment in 
adult life.1,2 Although ADHD is highly heritable, no 
speciﬁ c susceptibility genes have been unequivocally 
identiﬁ ed.1,2 Despite high heritability, neurodevelopmental 
features, and associated learning diﬃ  culties, some persist 
in arguing that the disorder is mainly a social construct.3,4 
There is now clear evidence that submicroscopic 
chromosomal structural abnormalities, often referred to 
as copy number variants (CNVs), are an important source 
of genetic variation,5 and that large, rare CNVs contribute 
to other neurodevelopmental disorders including 
intellectual disability, schizophrenia, and autism.6–11 
Although some have postulated that rare CNVs might be 
involved in ADHD,12 no speciﬁ c variant has yet been 
implicated in the disorder, and there are as yet no reports 
of an increased burden of CNVs in ADHD.
To investigate CNVs in ADHD, we studied a UK sample 
of carefully phenotyped children with ADHD and 
unrelated ethnically matched controls. Our ﬁ rst aim was 
to examine whether children with ADHD had an 
increased burden of CNVs compared with controls, and 
to test whether this increase was attributable to associated 
intellectual disability since ADHD, similarly to autism 
and schizophrenia, occurs with increased frequency in 
individuals with intellectual disability (IQ test score 
<70).13–15 Our second aim was to investigate whether 
identiﬁ ed CNVs in our ADHD sample were signiﬁ cantly 
enriched for a speciﬁ c chromosomal locus or loci 
previously implicated in autism and schizophrenia.
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Methods
Participants
This study was approved by Wales and northwest England 
multicentre research ethics committees. 410 children 
thought to have ADHD were consecutively recruited 
from 90 community child psychiatry and paediatric 
outpatient clinics across the UK between 2001 and 2009. 
All were of white UK origin (including parents and 
grandparents), aged 5–17 years, and met Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-IV or 
International Classiﬁ cation of Diseases (ICD)-10 criteria 
for ADHD or hyperkinetic disorder. Children with 
schizophrenia, Tourette’s syndrome, autistic spectrum 
disorder, or a neurological disorder including epilepsy 
were excluded. Diagnoses were conﬁ rmed with the Child 
and Adolescent Psychiatric Assessment,13 a research 
diagnostic interview. Interviews were undertaken by 
trained psychologists who were supervised weekly by a 
child psychiatrist. Inter-rater reliability for a diagnosis of 
ADHD was perfect (κ=1·0). Symptoms and impairment 
at school are a diagnostic requirement of the disorder, 
and we conﬁ rmed the presence of these criteria by 
interviewing the children’s teachers using the Child 
ADHD Teacher Telephone Interview.16 Of the 410 children 
recruited to the study, 375 were single cases, and 35 were 
known to have an aﬀ ected sibling (only one case from 
each pair was included). All children were screened with 
the autism screening questionnaire and individuals with 
suspected autistic spectrum disorder were excluded.
Since CNVs occur with increased frequency in patients 
with unexplained intellectual disability,17 we needed to 
exclude the possibility that any increased rate of CNVs 
recorded for these disorders was not a result of 
comorbidity with intellectual disability. Therefore, 
assessments of intellectual ability were undertaken for 
the ADHD group. Intellectual disability was assessed 
with the Wechsler Intelligence Scale for Children-IV,18 
and complete test scores were available for 396 children. 
In accordance with DSM-IV and ICD-10, individuals with 
IQ test scores lower than 70 were regarded as having 
intellectual disability.
Control genotype data were available for 1156 individuals 
(594 men, 562 women) born in the UK during one week 
in 1958 (the 1958 British Birth Cohort). All available data 
were included. The sample was genotyped by the 
Wellcome Trust Case-Control Consortium,19 from whom 
we obtained permission to use the data. Psychiatric data 
were not available for the control cohort. For disorders of 
low frequency (1–2% prevalence of ADHD), the eﬀ ect of 
unscreened controls would be negligible. Over-
representation of aﬀ ected individuals in the control 
sample would only reduce power to detect association.
Replication was sought in an independent dataset of 
825 Icelandic patients with ADHD (238 female and 
587 male participants) from deCODE Genetics. All 
participants met DSM-IV criteria for ADHD 
(477 combined type, 250 inattentive type, 58 hyperactive-
impulsive type, 40 unspeciﬁ ed), and those with 
schizophrenia and autism were excluded from the 
sample. Participants were recruited from outpatient 
paediatric, child, and adult psychiatry clinics in Iceland, 
and diagnoses had been made on the basis of standardised 
diagnostic assessments and had been reviewed by 
experienced clinicians.20,21 These participants were 
compared with 35 243 Icelandic controls, also from 
deCODE Genetics. CNV analysis in this sample has been 
previously described.22
Laboratory procedures
Single nucleotide polymorphisms (SNPs) were genotyped 
in the ADHD group with the Illumina (San Diego, CA, 
USA) Human660W-Quad BeadChip and in the control 
group with the HumanHap550 BeadChip. BeadStudio 
(version 2.0) was used to call genotypes, normalise the 
signal intensity data, and establish the log R ratio and B 
allele frequency at every SNP according to the standard 
Illumina protocols. All samples passed a standard SNP-
based quality control procedure; all samples with a SNP 
call rate lower than 0·95, any duplicate or related samples 
(proportion identical by descent [IBD] >0·03), or any 
potentially contaminated samples (proportion IBD >0·03 
with multiple samples) were excluded.
We undertook several analytic and validation measures 
to ensure that the results were not aﬀ ected by variation in 
the performance of the two SNP arrays, including cross-
platform analysis of CNV calls in 45 samples for which 
data were available for both BeadChips. We limited 
CNV analysis to 561 113 autosomal SNPs common to 
both SNP arrays. CNVs were deﬁ ned by PennCNV 
(2009Aug27version).23 Called CNVs were required to span 
at least 15 consecutive informative SNPs; those with copy 
number calls lower than two were classed as deletions, 
and greater than two as duplications. As is customary for 
this type of analysis,10,11 samples for which high-quality 
data could not be obtained were excluded on the basis of 
either a high SD in their genome-wide log R ratio (>0·30) 
or because they carried more than 30 apparent CNVs 
larger than 100 kb. These exclusions left 366 patients with 
ADHD and 1047 controls for full analyses. These samples 
had minimum diﬀ erence in the distribution of the mean 
SNP call rate (cases=0·999, SD=0·001; controls=0·992, 
SD=0·005) or the mean SD of the genome-wide log R 
ratio (cases=0·19, SD=0·03; controls=0·21, SD=0·03).
Large CNVs can be split by CNV calling algorithms; as 
is customary to overcome this issue, adjacent CNV calls 
were merged.10 We merged adjacent CNV calls larger than 
200 kb that occurred in a single individual where the gap 
was less than 50% of the entire length of the newly merged 
CNV. The log R ratio and B allele frequency of SNPs 
spanning all CNVs generated from merging adjacent calls 
were manually inspected before acceptance. At loci where 
the log R ratio and B allele frequency did not support the 
presence of a split, adjacent CNVs were not merged 
(eg, heterozygote genotype calls between adjacent 
For the 1958 British Birth 
Cohort see http://www.
b58cgene.sgul.ac.uk
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hemizygous CNVs). In keeping with previous studies,10 
we excluded CNVs for which more than 50% of their 
length spanned known gaps of at least 200 kb in the SNP 
array, genomic segments containing more than 14 CNVs 
(ie, >1% frequency) in the combined patients and controls, 
known segmental duplications present in the March, 2006 
human reference sequence (National Center for 
Biotechnology Information reference build 36.1, hg18), or 
known common CNVs deﬁ ned by the Genome Structural 
Variation Consortium.
Analysis of eight children with ADHD and three 
controls genotyped in duplicate established perfect 
concordance between CNVs larger than 200 kb called in 
the duplicate samples (n=9). Analysis of CNVs called in 
45 HapMap CEU samples (Utah residents with ancestry 
from northern and western Europe) that had been 
genotyped and supplied by Illumina with both the 
Human660W-Quad and HumanHap550 BeadChips also 
showed 100% concordance between the 12 rare CNVs 
larger than 200 kb identiﬁ ed. We noted no signiﬁ cant 
diﬀ erences in the frequency of large rare CNVs between 
samples extracted from blood and those extracted from 
saliva, or in the frequency with which CNVs were called in 
male compared with female participants in either the 
ADHD or control groups (all data available from NMW). 
Finally, as a highly conservative measure we accepted for 
analysis only CNVs larger than 500 kb. Large CNVs are 
called with greatest accuracy and show good concordance 
across diﬀ erent platforms.11,24 Large CNVs also show the 
most robust evidence for association with neuro-
developmental disorders such as schizophrenia.9–11,22
As a further measure, all large CNVs identiﬁ ed in the 
ADHD group were additionally tested with custom 
Agilent Human Genome comparative genomic hybrid-
isation (CGH) 44K microarrays (CA, USA) enriched for 
probes at each of the loci harbouring a CNV larger than 
500 kb. This procedure was done at Oxford Gene 
Technologies (Oxford, UK) in accordance with standard 
protocols. CGH analysis failed for two samples, each 
carrying one CNV. Of the 57 rare CNVs larger than 500 kb 
with high-quality CGH data, only two were not validated. 
Of the controls, 940 (carrying 71 of the 78 CNVs identiﬁ ed) 
had previously undergone independent CNV analysis 
with Aﬀ ymetrix 250K NspI and StyI arrays (CA, USA).11 
68 of the 71 rare CNVs larger than 500 kb that we identiﬁ ed 
in these samples were also identiﬁ ed by the Aﬀ ymetrix 
platform.11 To be conservative, we excluded the two CNVs 
in the ADHD group that were not conﬁ rmed by high-
quality data on the second platform (leaving a total of 57), 
whereas we included all 78 CNVs in the control group 
including those that were not conﬁ rmed by the Aﬀ ymetrix 
platform. Importantly, any bias arising from this approach 
will be against our hypothesis of an excess of CNVs 
in ADHD.
Statistical analysis
All analyses included rare CNVs larger than 500 kb. The 
genome-wide burden of CNVs was ﬁ rst assessed according 
to the average number of CNVs per sample. Signiﬁ cance 
of the burden comparisons was assessed via permutation 
(100 000 permutations, one-sided test) using PLINK 
(version 1.06)25 with analyses undertaken for all rare, large 
CNVs as well as stratiﬁ ed according to CNV type (deletion 
or duplication). For locus-speciﬁ c tests of association, we 
ﬁ rst deﬁ ned test regions according to the genomic 
boundaries for each CNV identiﬁ ed in the entire sample. 
When several CNVs identiﬁ ed in diﬀ erent samples 
overlapped, they were merged to create one locus that 
encompassed all overlapping CNVs. We then established 
the number of CNVs present within each test region in 
the patients and controls. Our analyses are based on rates 
of CNVs per patient, but to facilitate clinical interpretation, 
we also provide results for the percentage of individuals 
carrying large, rare CNVs.
To assess whether the CNVs identiﬁ ed in our ADHD 
cohort were signiﬁ cantly enriched for loci previously 
implicated in autism and schizophrenia, we ﬁ rst deﬁ ned 
the genomic coordinates for a list of 14 loci enriched for 
All CNVs Deletions only Duplications only
ADHD Controls Ratio p value ADHD Controls Ratio p value ADHD Controls Ratio p value
All ADHD and controls*
Number of CNVs 57 78 ·· ·· 15 13 ·· ·· 42 65 ·· ··
Rate 0·156 0·075 2·09 8·9×10–⁵ 0·041 0·012 3·30 0·0018 0·115 0·062 1·85 0·0016
ADHD (IQ ≥70) and controls†‡
Number of CNVs 40 78 ·· ·· 10 13 ·· ·· 30 65 ·· ··
Rate 0·125 0·075 1·68 0·0077 0·031 0·012 2·58 0·031 0·094 0·062 1·51 0·0387
ADHD (IQ <70) and controls†§
Number of CNVs 14 78 ·· ·· 4 13 ·· ·· 10 65 ·· ··
Rate 0·424 0·075 5·69 2·0×10-⁶ 0·121 0·012 10·10 0·0012 0·303 0·062 4·88 0·00020
Rate is the average number of CNVs per person. p values are empirical and one-sided. CNV=copy number variant. ADHD=attention-deﬁ cit hyperactivity disorder. 
*366 participants with ADHD, 1047 controls. †IQ data were unavailable for 14 participants with ADHD. ‡319 participants with ADHD, 1047 controls. §33 participants with 
ADHD and intellectual disability, 1047 controls.
Table 1: Global burden of large, rare CNVs
For the Genome Structural 
Variation Consortium CNV 
discovery project see http://
projects.tcag.ca/variation/
ng42m_cnv.php
For more on the International 
HapMap project see http://
hapmap.ncbi.nlm.nih.gov/
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CNVs associated with autism7,26–30 and six for 
schizophrenia.9,10,22,31 Apart from 16p11, all autism and 
schizophrenia loci were independent. After counting the 
number of CNVs larger than 500 kb in the patients and 
controls (conservatively, we did not stratify by CNV type) 
that overlapped with any of these test regions, we 
performed locus-speciﬁ c tests of association using PLINK 
(10 000 permutations, one-sided). We also tested the 
overall signiﬁ cance of case-control comparisons for the 
total burden of CNVs at these loci using logistic regression 
analysis. To allow for the possibility that any signiﬁ cant 
overlap was caused by diﬀ erences in the size of CNVs in 
the ADHD and control groups, we included CNV size as 
an independent variable.
Finally, we undertook locus-speciﬁ c tests of association 
using PLINK25 again with signiﬁ cance assessed via 
permutation (1 000 000 permutations, one-sided).10 In view 
of the very small cell sizes, we calculated approximate 
odds ratios for locus-speciﬁ c tests after the addition of 
0·5 before computing the log odds-ratio estimate.10
Role of the funding source
The sponsors of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. NMW and AT had full access to all 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication. HS had full access to 
all Icelandic replication data.
Results
366 children with ADHD and 1047 controls with high-
quality SNP array data were included in the ﬁ nal analysis. 
Children with ADHD (316 boys, 50 girls) had a mean age 
of 10·5 years (range 5–17; SD 2·72) and a mean IQ of 86 
(range 43–123; SD 13·89). 33 participants with intellectual 
disability (IQ <70, n=33, mean IQ=60) were identiﬁ ed. 
After exclusion of common (minor allele frequency >0·01) 
CNVs, all association analyses included the remaining 
135 rare CNVs larger than 500 kb (57 in patients and 78 in 
controls; table 1 and webappendix p 2).
We identiﬁ ed a highly signiﬁ cant excess of large, rare 
CNVs in children with ADHD compared with control 
participants, with the average number of CNVs per child 
with ADHD being 2·09 times higher than that in controls 
(p=8·9×10–⁵; table 1). 50 (14%) aﬀ ected children were 
shown to carry a CNV larger than 500 kb, compared with 
75 (7%) controls. In each of the ADHD and control 
samples, the rates of CNVs did not diﬀ er between male 
and female participants (data not shown; results available 
from NMW).
The enrichment of large, rare CNVs was greatest in the 
children with ADHD and intellectual disability, in whom 
the average number of CNVs per patient was 5·69 times 
higher (p=2·0×10–⁶) than that in the control group (table 1). 
12 (36%) children with ADHD and intellectual disability 
carried a CNV larger than 500 kb, compared with 38 (11%) 
of those without intellectual disability. Nevertheless, 
despite a signiﬁ cant diﬀ erence in the rates of CNVs in the 
children with ADHD with and without intellectual 
disability (p=0·00099, two-tailed test), large, rare CNVs 
were still signiﬁ cantly enriched by 1·68 times (p=0·0077) 
in those without intellectual disability (n=319, mean 
IQ=89) when compared with the control group (table 1). 
Irrespective of the presence or absence of intellectual 
disability, children with ADHD had a signiﬁ cant excess of 
both deletions and duplications (table 1). Finally, when 
genomic DNA was available for both parents, we examined 
the inheritance of each large, rare CNVs (12 ADHD 
probands without intellectual disability). Of 15 CNVs, four 
were de novo, six were inherited from the mother, and 
ﬁ ve from the father (webappendix p 2).
In an analysis restricted to children with ADHD without 
intellectual disability, eight of 40 CNVs larger than 500 kb 
identiﬁ ed in the ADHD group overlapped with a locus 
Figure 1: CNVs identiﬁ ed at chromosome 16p13.11
Log R ratio and B allele frequency plots of the six copy number variants 
(CNVs; all duplications) larger than 500 kb identiﬁ ed at the chromosome 
16p13.11 region in participants with attention-deﬁ cit hyperactivity disorder. 
Description UK Iceland
ADHD Controls p value* ADHD Controls p value†
Loci implicated in autism
chr1:174.1–175.1 1q25.1‡7 0 0 1 0 0 1
chr2:13.12–13.16 2p24.3§7 0 0 1 0 0 1
chr2:49.99–51.12 NRXN129 0 0 1 0 1 1
chr3:2.11–3.08 CNTN428 2 0 0·14 1 15 0·41
chr3:4.37–4.49 SUMF17 2 0 0·14 0 0 1
chr3:122.83–122.87 3q13.33‡7 0 0 1 0 0 1
chr3:174.59–175.49 NLGN17 1 0 0·61 0 2 1
chr4:144.85–144.85 4q31.21§7 0 0 1 0 0 1
chr6:161.68–163.07 PARK27 0 0 1 0 13 1
chr7:68.69–69.88 AUTS230 1 0 0·61 0 3 1
chr10:87.33–88.12 GRID17 0 0 1 1 1 0·063
chr15:23.12–23.24 UBE3A7 1 0 0·61 0 2 1
chr16:29.55–30.08 16p11.2‡27 1 1 0·87 1 22 0·53
chr22:49.44–49.52 SHANK326 0 0 1 0 0 1
Total CNVs overlapping ·· 8 1 0·0095¶ 3 59 0·32†
Total CNVs not overlapping ·· 32 77 ·· 60 1816 ··
Loci implicated in schizophrenia
chr1:144.94–146.29 1q21.1‡9,10 0 1 1 3 18 0·028
chr15:20.31–20.78 15q11.2‡9 0 0 1 10 245 0·31
chr15:28.72–30.3 15q13.2-13.3‡9,10 2 0 0·064 0 18 1
chr16:15.38–16.20 16p13.11‡22 6 1 0·0012 4 36 0·038
chr16:29.55–30.08 16p11.231 1 1 0·87 1 22 0·53
chr22:17.5–20.0 22q11.21‡9,10 0 1 1 3 18 0·028
Total CNVs overlapping ·· 9 4 0·010¶ 21 367 0·0081†
Total CNVs not overlapping ·· 31 74 ·· 42 1508 ··
CNV=copy number variant. ADHD=attention-deﬁ cit hyperactivity disorder. NRXN1=neurexin 1. CNTN4=contactin 4. 
SUMF1=sulphatase modifying factor 1. NLGN1=neuroligin 1. PARK2=parkin. AUTS2=autism susceptibility candidate 2. 
GRID1=glutamate receptor. UBE3A=ubiquitin ligase E3A. SHANK3=SH3 and multiple ankyrin repeat domains 3. 
*Empirical (one-tailed). †Fisher’s exact test (one-tailed). ‡Locus spans a contiguous set of genes. §Locus contains no 
known genes. ¶Logistic regression correcting for CNV size.
Table 2: Overlap between CNVs identiﬁ ed in ADHD (IQ>70) and loci implicated in autism and schizophrenia
See Online for webappendix
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previously implicated in autism,7,26–30 compared with only 
one of 78 in controls (p=0·0095; table 2). No speciﬁ c 
single autism locus showed a signiﬁ cant excess of CNVs 
in children with ADHD (table 2). We also found that of 
the CNVs identiﬁ ed in ADHD, nine of 40 overlapped with 
a locus previously implicated in schizophrenia 
(p=0·010).9,10,22,31 Locus-speciﬁ c tests revealed that this 
ﬁ nding was largely due to the 16p13.11 region (p=0·0012), 
where we identiﬁ ed six duplications in participants with 
ADHD (table 2; ﬁ gure 1 and ﬁ gure 2). Logistic regression 
analysis showed no signiﬁ cant association between CNV 
size and overlap with autism (two-sided p=0·41) or 
schizophrenia loci (p=0·90).
To ensure that subsequent ﬁ ndings related to ADHD 
rather than comorbid intellectual disability, we restricted 
genome-wide locus-speciﬁ c tests to participants without 
intellectual disability. A locus on chromosome 16p13.11 
(chr16:15156431-18174650) showed a signiﬁ cant excess of 
rare CNVs larger than 500 kb in children with ADHD 
(p=0·0008 corrected for multiple testing of all CNV loci 
by permutation; OR 13·88, 95% CI 2·3–82·2). Post-hoc 
analysis revealed that the excess of CNVs at this locus was 
due to duplications (corrected p=0·0001), which spanned 
an 824 kb consensus region (chr16:15 385 551–16 209 503; 
ﬁ gure 2). Analysis of DNA from both parents for two 
ADHD probands carrying 16p13.11 duplications revealed 
one to be maternally inherited and the other to be de novo 
(webappendix p 2). No duplications in this region were 
identiﬁ ed in our control sample. This consensus region is 
ﬂ anked by segmental duplications, spans only seven 
genes, and has been implicated in schizophrenia.22
We next sought replication of our ﬁ nding of an excess 
of chromosome 16p13.11 duplications in an independent 
dataset of 825 Icelandic patients with ADHD and 
35 243 Icelandic controls.22 In this second sample, there 
was a signiﬁ cant excess (p=0·031 after correction for 
relatedness and potential population stratiﬁ cation32) of 
chromosome 16p13.11 duplications in the ADHD group 
(n=4; frequency, 0·48%) compared with controls (n=36; 
frequency, 0·09%). Analysis of the Icelandic data also 
revealed that the CNVs identiﬁ ed in the ADHD sample 
were signiﬁ cantly enriched for loci previously implicated 
in schizophrenia (p=0·0081), but not autism (p=0·32; 
table 2).
Discussion
Using a well characterised sample, we show that children 
with ADHD have a signiﬁ cantly increased burden of 
large, rare CNVs that include both duplications and 
deletions. Importantly, since CNV burden is increased 
in people with unexplained intellectual disability, autism, 
and schizophrenia, our clinical assessment procedure 
allowed us to conclude that the CNV burden is not 
attributable to comorbidity with these disorders. 
Although ADHD is one of the most heritable psychiatric 
disorders, with a heritability estimate of 76%,1,2 genome-
wide association and linkage studies have so far failed to 
identify common genetic risk variants. Our results 
suggest that further investigation of rare CNVs in ADHD 
is likely to be fruitful. Up to now, there has been only 
one reported investigation of CNVs in ADHD, which did 
not detect a signiﬁ cantly increased burden of rare CNVs 
in 335 patients with the disorder.12 However, that study 
examined CNVs of all sizes rather than large CNVs, 
which are the ones that are most likely to be deleterious24 
and are particularly enriched in neurodevelopmental 
disorders such as schizophrenia.9–11
We also showed that large, rare CNVs identiﬁ ed in our 
ADHD cohort were signiﬁ cantly enriched for 
chromosomal loci previously implicated in autism and 
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Figure 2: Positions of CNVs identiﬁ ed at chromosome 16p13.11
The positions of rare copy number variants (CNVs) larger than 500 kb identiﬁ ed at the chromosome 16p13.11 region. Green lines show the six duplications identiﬁ ed in patients with attention-deﬁ cit 
hyperactivity disorder and the red line shows the deletion identiﬁ ed in a single control. The consensus region that is spanned by all CNVs is shown by the arrow. Orange bars show known segmental 
duplications and therefore the most likely location of the breakpoints for the CNVs identiﬁ ed. The relative locations of genes are based on National Center for Biotechnology Information reference 
build 36.1 in the University of California Santa Cruz (UCSC) Genome Browser.
For the UCSC Genome Browser 
see http://genome.ucsc.edu/
Articles
www.thelancet.com   Vol 376   October 23, 2010 1407
schizophrenia. ADHD is currently thought to be entirely 
separate from these disorders. However, there is some 
overlap between ADHD and autism in terms of clinical 
symptoms and cognitive deﬁ cits.33 Autistic traits and 
ADHD behaviours in the general population (not clinical 
disorder) also seem to be aﬀ ected by shared heritability.34 
Our results suggest that there could also be a shared 
biological basis to these two childhood-onset disorders. 
So far, possibly because of the dearth of relevant studies, 
there are no clinical or genetic data clearly pointing to 
overlap between ADHD and schizophrenia. In view of 
the strong evidence for association between duplications 
at 16p13.11 and schizophrenia,22 we note with particular 
interest that our ADHD cohort was signiﬁ cantly enriched 
for duplications at the same locus, a ﬁ nding that was 
independently replicated in the Icelandic population. 
Moreover, further analysis of two duplications at 16p13.11 
revealed that one was de novo, adding further support 
that this locus is functionally relevant to ADHD. Future 
studies analysing the segregation patterns of familial 
CNVs will be needed to estimate disease penetrance.
The consensus duplicated region at 16p13.11 spans 
only seven genes and is ﬂ anked by segmental 
duplications that predispose to recurrent chromosomal 
rearrange ments (ﬁ gure 2). The genes mapping within 
16p13.11 therefore provide a speciﬁ c focus for further 
research into the neurobiology of ADHD. Among the 
genes spanned by the CNV, NDE1 (nuclear distribution 
gene E homologue 1) is of particular interest because of 
its role in neurodevelopment and interaction with DISC1 
(disrupted in schizophrenia 1), a gene implicated in 
schizophrenia and other major psychiatric disorders that 
encodes a protein also involved in neurodevelopmental 
processes.35,36 Other investigators have detected CNVs 
spanning this region; deletions have been strongly 
associated with intellectual disability,17,37 whereas 
duplications have been detected in patients with autism,38 
intellectual disability,17,38 and schizophrenia,10,11 again 
suggesting that the same large, rare CNVs might 
contribute to several, phenotypically diﬀ erent neuro-
developmental disorders.
Our ﬁ ndings have important clinical and research 
implications. First, our results emphasise that further 
investigation of CNVs in ADHD is a priority for research 
into this disorder. We do not suggest, however, that the 
search for common genetic variants using SNPs should 
be abandoned because, up to now, SNP-based studies1 
have not had suﬃ  cient power to allow realistic 
assessment of the role of that class of variant in ADHD. 
Moreover, with the application of appropriate precautions 
such as we have undertaken, studies analysing SNPs 
and large, rare CNVs can be undertaken simultaneously. 
Key measures that allowed us to undertake such an 
analysis despite the use of two diﬀ erent SNP arrays 
were: that we limited our analysis to SNPs overlapping 
between platforms, we undertook quality-control checks 
in samples genotyped with both platforms, we validated 
the CNVs with independent platforms, and crucially, as 
our own cross-platform validation data show, we focused 
on CNVs large enough to be detected at high sensitivity 
and speciﬁ city irrespective of SNP array.
Second, the ﬁ ndings allow us to refute the hypothesis 
that ADHD is purely a social construct, which has 
important clinical and social implications for aﬀ ected 
children and their families. Finally, although the number 
of children with intellectual disability in our sample is 
small, more than a third carried a large, rare CNV. None 
of these participants had been assessed for this type of 
mutation by clinical services. Microarray-based com-
parative genomic hybridisation enables the accurate 
detection of submicroscopic CNVs and is increasingly 
being used to investigate patients with intellectual 
disability or congenital abnormalities in some clinical 
settings. Our results suggest that routine referral to 
clinical geneticists and screening for such mutations 
could be helpful for children with ADHD and 
intellectual disability.
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